James M. Daly - 17 Jun 2026 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Director
Issuer ticker: MDGL
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:16:45 UTC
Prior SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mardi Dier, as Attorney-in-Fact

Key filing fact

James M. Daly filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jun 2026.

Key facts

This page summarizes James M. Daly's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 16:16.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001560782 Primary reporting owner

Daly James M

Relationship: Director
Address: C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Signature date: 18 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value
Shares: +454
Change %: +17%
Price: $0.000000^*
Shares after: 3,081
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDGL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +766
Change %
Price: $0.000000^*
Shares after: 766
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 766
Exercise price: $499.86
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

Footnote F2

The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.